What do you know today that you didn't know yesterday?

[arewethereyet]

I learned today that tattoos are for wimps and I am a wimp.

Right there with ya on that one.  sigh

How will we carry on?

[brewer]

I learned today that tattoos are for wimps and I am a wimp.

Right there with ya on that one.  sigh

How will we carry on?

You will become wayward sons?

[Nanny]

Will there will peace when we are gone?

[brewer]

Will there will peace when we are gone?

Depends on where you lay your head.

[The Valkyrie]

Don't you cry no more!


Dammit.

Now I want to rewatch Supernatural!

[The Valkyrie]

I learned today that tattoos are for wimps and I am a wimp.

Right there with ya on that one.  sigh

How will we carry on?

I'm gonna get a tat, now, and the Crybaby, or whatever the fuck his name is, can come after me.

Poor, dumb, bastard!

[brewer]

Don't you cry no more!

Not till they rise about the noise and confusion.

[brewer]

It's new to me, had never heard of strep zoo before.

https://www.wowt.com/2024/06/09/nebraska...infection/

[brewer]

There is a new selective gram-negative antibiotic being tested that could be a game changer, lolamicin. Kills the nasties and leaves the beneficial alone.

---

Infections caused by Gram-negative pathogens are increasingly prevalent and are
typically treated with broad-spectrum antibiotics, resulting in disruption of the gut
microbiome and susceptibility to secondary infections. There is a critical need for
antibiotics that are selective both for Gram-negative bacteria over Gram-positive
bacteria, as well as for pathogenic bacteria over commensal bacteria. Here we report
the design and discovery of lolamicin, a Gram-negative-specific antibiotic targeting
the lipoprotein transport system. Lolamicin has activity against a panel of more than
130 multidrug-resistant clinical isolates, shows efficacy in multiple mouse models of
acute pneumonia and septicaemia infection, and spares the gut microbiome in mice,
preventing secondary infection with Clostridioides difficile. The selective killing of
pathogenic Gram-negative bacteria by lolamicin is a consequence of low sequence
homology for the target in pathogenic bacteria versus commensals; this doubly
selective strategy can be a blueprint for the development of other microbiome-
sparing antibiotics.

---

https://www.nature.com/articles/s41586-0...dscape.com

[The Valkyrie]

There is a new selective gram-negative antibiotic being tested that could be a game changer, lolamicin. Kills the nasties and leaves the beneficial alone.

---

Infections caused by Gram-negative pathogens are increasingly prevalent and are
typically treated with broad-spectrum antibiotics, resulting in disruption of the gut
microbiome and susceptibility to secondary infections. There is a critical need for
antibiotics that are selective both for Gram-negative bacteria over Gram-positive
bacteria, as well as for pathogenic bacteria over commensal bacteria. Here we report
the design and discovery of lolamicin, a Gram-negative-specific antibiotic targeting
the lipoprotein transport system. Lolamicin has activity against a panel of more than
130 multidrug-resistant clinical isolates, shows efficacy in multiple mouse models of
acute pneumonia and septicaemia infection, and spares the gut microbiome in mice,
preventing secondary infection with Clostridioides difficile. The selective killing of
pathogenic Gram-negative bacteria by lolamicin is a consequence of low sequence
homology for the target in pathogenic bacteria versus commensals; this doubly
selective strategy can be a blueprint for the development of other microbiome-
sparing antibiotics.

---

https://www.nature.com/articles/s41586-0...dscape.com

I can do that.

With people, anyway...